ImageneBio, Inc. (IMA) Stock

NASDAQ: IMAHealthcare company in the biotechnology industry, based in San Diego, CA.

ImageneBio stock price chart

IMA interactive chart →

IMA stock quote & key statistics

ImageneBio earnings per share

Income →
Earnings per share

ImageneBio revenue & net income

Income →
RevenueNet income

ImageneBio annual financials

Income statement →
Fiscal yearRevenueNet incomeEPS
FY2025$800,000-$45.3M-$4.39
FY2024$3.5M-$36.6M-$1.02
FY2023$9.2M-$68.2M-$1.64
FY2022$15.6M-$68.8M-$1.91
FY2021$31.0M-$34.1M-$4.74

Fiscal year ending December 31. Source: company filings via EODHD.

About ImageneBio, Inc.

ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

ImageneBio stock FAQ

What is the ImageneBio stock ticker symbol?

ImageneBio, Inc. trades on the NASDAQ under the ticker symbol IMA.

What sector and industry is ImageneBio in?

ImageneBio, Inc. is classified in the Healthcare sector, Biotechnology industry.

How many employees does ImageneBio have?

ImageneBio, Inc. has about 18 full-time employees.

What were ImageneBio's revenue and earnings last fiscal year?

ImageneBio reported revenue of $800,000 and net income of -$45.3M in fiscal 2025, with earnings per share of -$4.39. Revenue declined 77.1% from the prior year.

When did ImageneBio go public?

ImageneBio stock began trading on March 26, 2021.

Biotechnology stocks

All Healthcare stocks →